Evidence map›Paper›PMID 35361184›Full record

ReviewBMC psychiatry2022

COVID-19 and substance use disorders: a review of international guidelines for frontline healthcare workers of addiction services.

Edoardo G Ostinelli, Katharine Smith, Caroline Zangani, Michael J Ostacher, Anne R Lingford-Hughes, James S W Hong, Orla Macdonald, Andrea Cipriani

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMC psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Liver fibrosis screening increases alcohol abstinence.JHEP reports : innovation in hepatology · 2024
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Edoardo G OstinelliDepartment of Psychiatry, University of Oxford, Oxford, UK. edoardo.ostinelli@psych.ox.ac.uk.
Katharine SmithDepartment of Psychiatry, University of Oxford, Oxford, UK.
Caroline ZanganiDepartment of Psychiatry, University of Oxford, Oxford, UK.
Michael J OstacherDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Anne R Lingford-HughesDivision of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.
James S W HongDepartment of Psychiatry, University of Oxford, Oxford, UK.
Orla MacdonaldOxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, UK.
Andrea CiprianiDepartment of Psychiatry, University of Oxford, Oxford, UK.

Funding

Department of Health
6 · The paper itself

Abstract

backgroundPeople with substance use disorders may be at a greater risk of contracting COVID-19 infection and developing medical complications. Several institutional and governmental health agencies across the world developed ad hoc guidance for substance use disorder services and care of individuals misusing substances. We aimed to synthesise the best available recommendations on management and care of people with or at risk of substance use disorders during the COVID-19 pandemic from existing guidelines published in UK, USA, Australia, Canada, New Zealand, and Singapore.

methodsWe systematically searched existing guidelines and websites from 28 international institutions and governmental bodies in the context of the COVID-19 pandemic (May 4

resultsWe organised the available recommendations from 19 sources in three sections. First, we focused on general advice and recommendations for people who misuse alcohol or drugs during the COVID-19 pandemic, the design of contingency plans, safeguarding issues for children and families of service users and advice to the public, patients, and carers. Then, we summarised specific guidelines for people who use illicit drugs and related services, such as opioid substitution treatment and needle and syringe programmes. Finally, we provided a synthesis on specific recommendations for services supporting people who misuse alcohol and key topics in the field, such as management of alcohol detoxification and safe transition between supervised and unsupervised consumption.

conclusionsAvailable guidance reflected different approaches, ranging from being extremely cautious in providing recommendations other than generic statements to proposing adaptation of previously available guidelines to confront the challenges of the COVID-19 pandemic. After the early phase, guidance focused on reduction of infection transmission and service delivery. Guidance did not provide advice on infection prevention via vaccination programmes and service access strategies tailored to individuals with substance use disorders.

Indexed as

AlcoholismCOVID-19Substance-Related DisordersChildGuidelines as TopicHealth PersonnelHumansPandemicsAlcoholCOVID-19Evidence-base recommendationsGuidelinesNeedle and syringe programmeOpioid substitution treatmentSubstance use disorder

Identifiers

PMID35361184
PMCPMC8968241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.